C. Guérois

发表

Epidemiological survey of haemophiliacs with inhibitors in France: orthopaedic status, quality of life and cost – the ‘Statut Orthopédique des Patients Hémophiles’ avec Inhibiteur study

T. Lambert, M. Bertrand, A. Borel‐Derlon, 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Incidence of Factor VIII Inhibitor Development in Severe Hemophilia A Patients Treated only with One Brand of Highly Purified Plasma-Derived Concentrate

C. Rothschild, M. Bertrand, C. Négrier, 1995, Thrombosis and Haemostasis.

French Previously Untreated Patients with Severe Hemophilia A after Exposure to Recombinant Factor VIII : Incidence of Inhibitor and Evaluation of Immune Tolerance

P. Moreau, C. Rothschild, J. Goudemand, 1998, Thrombosis and Haemostasis.

Incidence of Factor IX Inhibitor Development in Severe Haemophilia B Patients Treated with only one Brand of High Purity Plasma Derived Factor IX Concentrate

C. Rothschild, V. Gay, C. Guérois, 1999, Thrombosis and Haemostasis.

Detection and IgG subclass analysis of antibodies to factor VIII in multitransfused haemophiliacs and healthy individuals

C. Guérois, Y. Sultan, A. Parquet‐Gernez, 1996, Haemophilia : the official journal of the World Federation of Hemophilia.

Factor VIII recovery after a single infusion of recalibrated ReFacto® in 14 severe haemophilia A patients

T. Lambert, M. Bertrand, V. Gay, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Treatment of Heparin-Associated Thrombocytopenia and Thrombosis with Low Molecular Weight Heparin (CY 216)

Y. Gruel, C. Guérois, J. Leroy, 1985, Seminars in thrombosis and hemostasis.

Acquired inhibitor to factor VIII in a patient with Hodgkin’s disease following treatment with interferon‐alpha

Y. Gruel, P. Colombat, C. Guérois, 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

ANTIBODIES TO HEPATITIS C VIRUS IN HAEMOPHILIA

P. Maisonneuve, C. Guérois, Y. Laurian, 1989, The Lancet.

Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors.

P. Moreau, T. Lambert, C. Rothschild, 2006, Seminars in hematology.

Comparison of Anti‐Human and Anti‐Porcine Factor VIII Inhibitor Levels in 63 Patients with Severe Haemophilia A

M. Torchet, M. Bertrand, B. Boneu, 1993, Vox sanguinis.

Patient resources in the therapeutic education of haemophiliacs in France: their skills and roles as defined by consensus of a working group

T. Lambert, A. Borel‐Derlon, S. Meunier, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Compliance with Early Long-Term Prophylaxis Guidelines for Severe Hemophilia A.

K. Baumstarck, P. Moreau, T. Lambert, 2021, The Journal of pediatrics.

A Cross-over Pharmacokinetic Study of a Double Viral Inactivated Factor IX Concentrate (15 nm Filtration and SD) Compared to a SD Factor IX Concentrate

J. Goudemand, C. Négrier, H. Chambost, 1998, Thrombosis and Haemostasis.

[French guidelines. Long-term prophylaxis for severe haemophilia A and B children to prevent haemophiliac arthropathy].

C. Rothschild, C. Berger, A. Borel‐Derlon, 2009, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

Comparison of Anti-Human and Anti-Porcine Factor Vlll Inhibitor

M. Torchet, M. Bertrand, B. Boneu, 2009 .

[Efficacy in viral inactivation of the concentrates of factor VIII and IX by the solvent/detergent procedure. Evaluation in patients with hemophilia].

C. Guérois, Y. Laurian, M. Vicariot, 1991, Presse medicale.

Prevalence and significance of hepatitis C virus (HCV) viremia in HCV antibody-positive subjects from various populations

J. Tichet, Y. Bacq, A. Goudeau, 1993, Journal of clinical microbiology.

Antibody to hepatitis C (anti C 100-3) in French hemophiliacs.

C. Guérois, Y. Laurian, A. Couroucé, 1991, Nouvelle revue francaise d'hematologie.

The white clot syndrome or heparin associated thrombocytopenia and thrombosis (WCS or HATT) (26 cases).

Y. Gruel, C. Guérois, J. Leroy, 1985, International Angiology.

Immunologic and virologic status of multitransfused patients: role of type and origin of blood products. By the AIDS-Hemophilia French Study Group.

A. Goudeau, C. Guérois, Y. Laurian, 1985, Blood.

Hepatitis A in French Hemophiliacs

J. Fonlupt, J. Goudemand, C. Négrier, 1994, Vox sanguinis.

ANALYSIS OF THE RISK OF TRANSMISSION OF VARIANT OF CREUTZFELDT-JAKOB DISEASE BY HEALTH PRODUCTS AND BY TISSUES AND FLUIDS OF HUMAN ORIGIN

J. Hauw, C. Négrier, N. Ifrah, 2006 .

[Anti-HCV and recipients: situation in hemophiliacs in 1991].

C. Guérois, Y. Laurian, A. Parquet‐Gernez, 1992, Revue francaise de transfusion et d'hemobiologie : bulletin de la Societe nationale de transfusion sanguine.

The kinetics of antibodies against hepatitis C virus may predict viral clearance in exposed hemophiliacs.

Y. Gruel, Y. Bacq, A. Goudeau, 1998, The Journal of infectious diseases.